Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.
There are no adequate studies in pregnant women. Budesonide should only be used in pregnant women if the benefits outweigh the unknown risk. Use of budesonide
during pregnancy may suppress the adrenal glands of the infant.
Budesonide is secreted in human breast milk. Because of the potential for adverse reactions in
nursing infants from any corticosteroid, a decision should be made whether to discontinue nursing or discontinue the budesonide.
STORAGE: Capsules should be stored between 15 C to 30 C (59 F to 86 F)
The recommended dose for active Crohn's disease is 9 mg once daily in the morning for up to 8 weeks.
The 8 week course may be repeated for recurring episodes.
The dose for maintenance of remission is 6 mg once daily for 3 months.
The recommended dosage for the induction of remission in adult patients with active, mild to moderate
ulcerative colitis is one 9 mg extended release tablet to be taken once daily in the morning for up to 8 weeks.
DRUG CLASS AND MECHANISM:
Budesonide is a synthetic (man-made) steroid of the glucocorticoid family that is used for treating
Crohn's disease. The naturally-occurring hormone whose actions budesonide mimics, is cortisol or hydrocortisone which is produced by the adrenal glands. Glucocorticoid steroids have potent anti-inflammatory actions.
Crohn's disease is a chronic
inflammatory bowel disease of unknown cause that results in
fever and bleeding from the rectum. The active ingredient in Budesonide, is released from granules in the
ileum of the small intestine and the right (proximal) colon, where the inflammation of
Crohn's disease occurs. Budesonide acts directly by contact with the ileum and colon. Budesonide that is absorbed into the body travels first to the
liver where it is broken-down and eliminated from the body. This prevents the majority of the absorbed drug from being distributed to the rest of the body. As a result, budesonide causes fewer severe side effects throughout the body than other